Truist Financial Corp Purchases 95 Shares of Align Technology, Inc. $ALGN

Truist Financial Corp lifted its position in Align Technology, Inc. (NASDAQ:ALGN) by 2.3% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,227 shares of the medical equipment provider’s stock after buying an additional 95 shares during the quarter. Truist Financial Corp’s holdings in Align Technology were worth $800,000 as of its most recent filing with the SEC.

A number of other large investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in Align Technology by 2.2% during the first quarter. Vanguard Group Inc. now owns 8,441,592 shares of the medical equipment provider’s stock worth $1,341,031,000 after purchasing an additional 185,187 shares during the period. Ninety One UK Ltd raised its stake in shares of Align Technology by 58.7% in the first quarter. Ninety One UK Ltd now owns 1,937,555 shares of the medical equipment provider’s stock valued at $307,800,000 after purchasing an additional 716,954 shares in the last quarter. Invesco Ltd. raised its stake in shares of Align Technology by 12.7% in the first quarter. Invesco Ltd. now owns 1,219,715 shares of the medical equipment provider’s stock valued at $193,764,000 after purchasing an additional 137,553 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Align Technology by 32.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 832,313 shares of the medical equipment provider’s stock worth $132,221,000 after acquiring an additional 202,616 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its stake in Align Technology by 0.7% during the first quarter. Jacobs Levy Equity Management Inc. now owns 736,635 shares of the medical equipment provider’s stock worth $117,022,000 after acquiring an additional 4,789 shares in the last quarter. Institutional investors own 88.43% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on ALGN. Wells Fargo & Company decreased their target price on Align Technology from $246.00 to $199.00 and set an “overweight” rating on the stock in a report on Thursday, July 31st. Piper Sandler decreased their price target on Align Technology from $250.00 to $190.00 and set an “overweight” rating on the stock in a report on Thursday, July 31st. Jefferies Financial Group reissued a “hold” rating and issued a $140.00 target price (down previously from $215.00) on shares of Align Technology in a research note on Friday. Weiss Ratings lowered Align Technology from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, October 8th. Finally, Stifel Nicolaus dropped their price target on Align Technology from $275.00 to $200.00 and set a “buy” rating on the stock in a research report on Thursday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $187.67.

Align Technology Trading Up 0.2%

Shares of NASDAQ ALGN opened at $129.79 on Wednesday. Align Technology, Inc. has a 12 month low of $122.00 and a 12 month high of $246.19. The stock has a 50 day moving average of $135.25 and a 200-day moving average of $163.94. The company has a market capitalization of $9.41 billion, a P/E ratio of 21.89, a P/E/G ratio of 1.47 and a beta of 1.70.

Align Technology (NASDAQ:ALGN) last released its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $2.49 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.57 by ($0.08). The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1.06 billion. Align Technology had a net margin of 11.04% and a return on equity of 13.36%. The business’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same quarter last year, the firm earned $2.41 earnings per share. Align Technology has set its Q3 2025 guidance at EPS. Analysts predict that Align Technology, Inc. will post 7.98 EPS for the current fiscal year.

Align Technology announced that its board has authorized a share repurchase plan on Tuesday, August 5th that authorizes the company to buyback $200.00 million in shares. This buyback authorization authorizes the medical equipment provider to repurchase up to 2% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board believes its stock is undervalued.

Insider Transactions at Align Technology

In other news, CEO Joseph M. Hogan purchased 7,576 shares of Align Technology stock in a transaction that occurred on Friday, August 1st. The stock was acquired at an average cost of $131.49 per share, for a total transaction of $996,168.24. Following the purchase, the chief executive officer directly owned 184,945 shares of the company’s stock, valued at $24,318,418.05. This trade represents a 4.27% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.66% of the stock is owned by company insiders.

Align Technology Company Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.